Healthcare provider profile · identity verified

Prince Pannu, MD

Family Practice · BELLINGHAM, WA · NPI 1629333471

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	415	113
Losartan Potassium	Losartan Potassium	199	53
Amlodipine Besylate	Amlodipine Besylate	163	46
Omeprazole	Omeprazole	161	47
Levothyroxine Sodium	Levothyroxine Sodium	160	40
Lisinopril	Lisinopril	142	41
Rosuvastatin Calcium	Rosuvastatin Calcium	107	36
Metoprolol Succinate	Metoprolol Succinate	100	28
Tamsulosin Hcl	Tamsulosin Hcl	97	29
Gabapentin	Gabapentin	94	32
Metformin Hcl	Metformin Hcl	77	24
Hydrochlorothiazide	Hydrochlorothiazide	76	19
Duloxetine Hcl	Duloxetine Hcl	75	19
Fluticasone Propionate	Fluticasone Propionate	66	31
Simvastatin	Simvastatin	59	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	51	23
Glipizide Er	Glipizide	51	13
Pantoprazole Sodium	Pantoprazole Sodium	51	17
Lovastatin	Lovastatin	50	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	48	30
Venlafaxine Hcl Er	Venlafaxine Hcl	47	suppressed
Sertraline Hcl	Sertraline Hcl	43	12
Ozempic	Semaglutide	41	suppressed
Metformin Hcl Er	Metformin Hcl	39	11
Fluoxetine Hcl	Fluoxetine Hcl	38	12
Pravastatin Sodium	Pravastatin Sodium	38	suppressed
Clonazepam	Clonazepam	35	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	33	suppressed
Trazodone Hcl	Trazodone Hcl	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Allopurinol	Allopurinol	31	12
Eliquis	Apixaban	31	suppressed
Pregabalin	Pregabalin	29	suppressed
Carvedilol	Carvedilol	27	12
Clopidogrel	Clopidogrel Bisulfate	27	12
Mirtazapine	Mirtazapine	27	suppressed
Naproxen	Naproxen	27	17
Bupropion Xl	Bupropion Hcl	26	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	25	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Furosemide	Furosemide	24	suppressed
Famotidine	Famotidine	23	suppressed
Colchicine	Colchicine	22	11
Methocarbamol	Methocarbamol	22	suppressed
Telmisartan	Telmisartan	22	suppressed
Azithromycin	Azithromycin	21	20
Chlorthalidone	Chlorthalidone	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Ketoconazole	Ketoconazole	21	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Ondansetron Odt	Ondansetron	21	suppressed
Atenolol	Atenolol	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Mounjaro	Tirzepatide	19	suppressed
Prednisone	Prednisone	19	17
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Azelastine Hcl	Azelastine Hcl	18	12
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Acyclovir	Acyclovir	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Propranolol Hcl Er	Propranolol Hcl	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Glipizide	Glipizide	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Cephalexin	Cephalexin	12	11
Donepezil Hcl	Donepezil Hcl	12	suppressed
Finasteride	Finasteride	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Risperidone	Risperidone	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Azelastine-Fluticasone	Azelastine/Fluticasone	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error